tbuckley/cabot-search huggingface dataset:
Can we diagnose MDS without bone marrow examination? A proposed EUMDS-based non-invasive diagnostic model
Authors: Howard S. Oster, Bander Abu Shrkihe, Simon Crouch, Alexandra Smith, Ge Yu, Gal Carmi, Jonathan Ben-Ezra, Shachar Naor, Pierre Fenaux, Argiris Symeonidis, Reinhard Stauder, Jaroslav Cermak, Guillermo Sanz, Eva Hellstrom-Lindberg, Luca Malcovati, Saskia Langemeijer, Ulrich Germing, Mette Skov Holm, Krzysztof Madry, Aurelia Tatic, Antonio Medina de Almeida, Aleksandar Savic, Njetočka Gredelj-Šimec, Agnes Guerci Bresler, Corine van Marrewijk, David T. Bowen, T. M. M de Witte, Moshe Mittelman
Journal: Blood (2017)
Consensus on a video analysis framework of descriptors and definitions by the Rugby Union Video Analysis Consensus group
Authors: Sharief Hendricks, Kevin Till, Steve den Hollander, Trevor N Savage, Simon P Roberts, Gregory Tierney, Nicholas Burger, Hamish Kerr, Simon Kemp, Matthew Cross, Jon Patricios, Andrew J McKune, Mark Bennet, Andy Rock, Keith A Stokes, Alex Ross, Clint Readhead, Kenneth L Quarrie, Ross Tucker, Ben Jones
Journal: British Journal of Sports Medicine (2020)

Using an expert consensus-based approach, a rugby union Video Analysis Consensus (RUVAC) group was formed to develop a framework for video analysis research in rugby union. The aim of the framework is to improve the consistency of video analysis work in rugby union and help enhance the overall quality of future research in the sport. To reach consensus, a systematic review and Delphi method study design was used. After a systematic search of the literature, 17 articles were used to develop the final framework that described and defined key actions and events in rugby union (rugby). Thereafter, a group of researchers and practitioners with experience and expertise in rugby video analysis formed the RUVAC group. Each member of the group examined the framework of descriptors and definitions and rated their level of agreement on a 5-point agreement Likert scale (1: strongly disagree; 2: disagree; 3: neither agree or disagree; 4: agree; 5: strongly agree). The mean rating of agreement on the five-point scale (1: strongly disagree; 5: strongly agree) was 4.6 (4.3-4.9), 4.6 (4.4-4.9), 4.7 (4.5-4.9), 4.8 (4.6-5.0) and 4.8 (4.6-5.0) for the tackle, ruck, scrum, line-out and maul, respectively. The RUVAC group recommends using this consensus as the starting framework when conducting rugby video analysis research. Which variables to use (if not all) depends on the objectives of the study. Furthermore, the intention of this consensus is to help integrate video data with other data (eg, injury surveillance).
Tumor infiltrating lymphocytes (TIL) assessment in muscle invasive bladder cancer (MIBC) patients treated with cisplatin-based neoadjuvant chemotherapy (NAC) and surgery.
Authors: Nieves Martinez Chanza, Anis Hamid, Roberto Salgado, Thomas Gevaert, Marion Maetens, Sandrine Rorive, Philippe Georges Aftimos, Spyridon Sideris, Thierry Gil, Ahmad Awada, Thierry Andre Roumeguere
Journal: Journal of Clinical Oncology (2020)

547 Background: Cisplatin-based NAC followed by surgery is the gold standard treatment of non-metastatic MIBC. However, predictive biomarkers have not been established yet. Here, we addressed the relevance of TILs for NAC response and prognosis in MIBC patients (pts). Methods: We conducted a single center, retrospective cohort analysis of consecutive MIBC pts treated with cisplatin-based NAC followed by surgery. Pts with pathological complete response (pCR; ypT0/isN0) were grouped as responders, pts with pathological residual disease as non responders. TIL stromal count were assessed pre- and post-NAC. Next Generation Sequencing of selected genes was performed on pre-NAC samples. We catalogued the 3-years(y) relapse free rate and 3-y overall survival rate (OS, Kaplan Meier) for the overall cohort and by subgroups. Results: Of the 25 pts who received cisplatin-gemcitabine NAC, a total of 14 (56%) pts achieved a pCR and 11 (44%) had residual disease. NAC was discontinued in 17 (65%) after completing treatment; and in 8 (32%) pts after 2 cycles due to toxicity. Median follow-up was 54.2 months(mos). At baseline, median TIL count was 60% in the overall cohort. Numerically higher TIL count was observed among responders (80%) compared to non-responders (50%) ( p=0.22). Median TIL count post-NAC in residual samples was 40%, not significantly different to matched pre-NAC samples ( p=0.93). Overall, 3-y relapse free rate was 74.7% (95%CI 51.7-87.9); 3-y OS rate was 79.6% (95%CI 57.6-91) with 6 deaths of which 4 were related to metastatic disease. Table reports subset analyses. Most frequently altered genes were PIK3CA and TP53 in the overall cohort (each 20%) and in the responders subgroup (each 29%). Conclusions: In our study, pts who achieved pCR had numerically greater TIL infiltrate in baseline samples and pCR was associated with reduced risk of recurrence. TILs did not increase in residual tumors after NAC. The independent predictive value of TILs warrants assessment in large cohorts.[Table: see text]
Comparative circulating tumor DNA (ctDNA) genomic profiling in 110 patients with advanced renal cell carcinoma.
Authors: Ritesh Kotecha, Erika Gedvilaite, Samuel J. Murray, Ashley Foster, Robert J. Motzer, Dana Tsui, Martin H Voss
Journal: Journal of Clinical Oncology (2020)

743 Background: Circulating tumor DNA (ctDNA) profiling is a non-invasive method to genomically assess solid tumors. Key benchmarks are required to assess applications in RCC management. To evaluate this tool broadly, we performed a large cohort analysis using a comparative approach to correlate clinical characteristics and matched oncogenomics of primary tumor and ctDNA. Methods: Pts with prior NGS sequenced mutational profiles from tumor (nephrectomy or metastatic tissues) underwent a single-time point plasma collection for ctDNA extraction. ctDNA targeted NGS sequencing was performed using MSK-IMPACT, with bi-directional cross genotype comparison using Waltz 2.0. Liberal (1-2 reads) and stringent (≥3 reads) filters were applied, with a cut-off of &lt;30% allele frequency to remove germline alterations. Relevant clinical parameters were analyzed for correlation with ctDNA alteration frequency and load. Results: 110 metastatic clear-cell RCC pts, of whom available IMDC-risk was favorable (25%), intermediate (45%), or poor (4%) were included. 96% of pts had a nephrectomy prior to ctDNA collection, and most were heavily pre-treated (mean: 3 therapies, R: 0-8). The median time from diagnosis to ctDNA collection was 22.1 months (R: 2.3-215), and the median time from site specific tissue sequencing was 23.8 months (R: 1-177). 587 alterations were identified across the entire cohort in primary tissues, and 65% of pts had ≥1 alteration in ctDNA by liberal criteria. Detection rates for VHL and PBRM1 alterations were different in primary tissue and ctDNA (both liberal and stringent) with VHL altered in 92%, 43% and 50%, respectively; and PBRM1 altered in 50%, 25%, 21%, respectively. Conclusions: This large cohort analysis shows comparable mutational profiles of RCC-specific alterations in primary tissue and ctDNA, and highlights challenges of liquid biopsy approaches in RCC. Future efforts to correlate clinical outcomes with algorithm-based metrics will enhance the utility of this tool.[Table: see text]
Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study.
Authors: Raksha Dutt, Margaret Frances Meagher, Dattatraya Patil, Kazutaka Saito, Devin Patel, Fady Ghali, Cathrine Keiner, Nathan Miller, Aaron Bradshaw, Fang Wan, Yosuke Yasuda, Yasuhisa Fujii, Viraj A. Master, Ithaar Derweesh
Journal: Journal of Clinical Oncology (2020)

666 Background: Functional decline is an important consideration in the surgical treatment of renal cell carcinoma (RCC). While radical nephrectomy (RN) may be associated with increased risk of functional decline compared to partial nephrectomy (PN), the modifying effect of DM, an independent risk factor of chronic kidney disease (CKD), is not completely understood. We investigated the relationship between DM and decline in kidney function following surgery for RCC, and impact on overall survival (OS) in patients with RCC. Methods: A multicenter dataset of RCC patients undergoing PN and RN was utilized. The cohort was divided based on DM status [DM vs No DM (NDM)]. Multivariable analysis (MVA) elucidated potential variables associated with decline in kidney function [de novo estimated glomerular filtration rate (eGFR) &lt; 45 ml/min/1.73m 2 and de novo eGFR &lt; 30 ml/min/1.73m 2 ] and worse all-cause mortality (ACM). Kaplan-Meier analysis (KMA) was used to investigate OS rates in DM and NDM patients undergoing RN and PN. Results: 2928 patients were analyzed (DM = 406, NDM = 2522). On MVA, independent risk factors associated with eGFR &lt; 45 included age (OR = 1.07, p &lt; 0.001), DM (OR = 1.88, p &lt; 0.001), tumor size (OR = 1.03, p = 0.032), and RN (OR = 1.54, p &lt; 0.001). Variables associated with eGFR &lt; 30 included age (OR = 1.05, p &lt; 0.001), African American race (OR = 2.18, p &lt; 0.001), and DM (OR = 2.09, p &lt; 0.001). MVA for ACM revealed age (OR = 1.02, p = 0.002), HTN (OR = 2.47, p &lt; 0.001), tumor size (OR = 1.12, p &lt; 0.001), tumor grade (OR = 1.87, p &lt; 0.001), RN (OR = 1.55, p = 0.011), eGFR &lt; 45 (OR = 1.40, p = 0.03), and eGFR &lt; 30 (OR = 1.87, p = 0.026) to be independently associated. On KMA, 5-year OS stratified by DM status showed that DM is associated with worse OS for RN patients (p = 0.047), but not for PN patients (p = 0.944). Conclusions: Presence of DM is an independent risk factor for renal functional decline and development of worsening CKD is a risk factor for worsening ACM. Furthermore, decreased survival in DM patients was associated with RN recipients but not with PN recipients. Presence of DM may be considered a strong indicator for nephron preservation management strategies when safe and feasible in RCC patients.
Serial Change In Pfts Is Predictive Of Outcome In Systemic Sclerosis Associated Interstitial Lung Disease
Authors: N Goh, T Corte, O Moore, H Rouse, O Hennessy, V Thakkar, J Sahhar, J Roddy, P Youssef, E Gabbay, P Nash, J Zochling, W Stevens, S Proudman, M Nikpour
Journal: American Journal of Respiratory and Critical Care Medicine (2014)
Reply to: “The age of procalcitonin: Potential pitfalls in critically ill patients with SJS/TEN. A comment on ‘Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients’”
Authors: Hui Kai Koh, Haur Yueh Lee
Journal: Journal of the American Academy of Dermatology (2020)
The protein S100A4 as a novel marker of insulin resistance in prepubertal and pubertal children with obesity
Authors: Augusto Anguita-Ruiz, Andrea Mendez-Gutierrez, Azahara I. Ruperez, Rosaura Leis, Gloria Bueno, Mercedes Gil-Campos, Inés Tofe, Carolina Gomez-Llorente, Luis A. Moreno, Ángel Gil, Concepción M. Aguilera
Journal: Metabolism (2020)
Serum Levels of Perfluoroalkyl Substances (PFAS) in Adolescents and Young Adults Exposed to Contaminated Drinking Water in the Veneto Region, Italy: A Cross-Sectional Study Based on a Health Surveillance Program
Authors: Gisella Pitter, Filippo Da Re, Cristina Canova, Giulia Barbieri, Maryam Zare Jeddi, Francesca Daprà, Flavio Manea, Rinaldo Zolin, Anna Maria Bettega, Giampaolo Stopazzolo, Silvia Vittorii, Lorena Zambelli, Marco Martuzzi, Domenico Mantoan, Francesca Russo
Journal: Environmental Health Perspectives (2020)

In spring 2013, groundwater of a vast area of the Veneto Region (northeastern Italy) was found to be contaminated by perfluoroalkyl substances (PFAS) from a PFAS manufacturing plant active since the late 1960s. Residents were exposed to high concentrations of PFAS, particularly perfluorooctanoic acid (PFOA), through drinking water until autumn 2013. A publicly funded health surveillance program is under way to aid in the prevention, early diagnosis, and treatment of chronic disorders possibly associated with PFAS exposure.
Cannabis Hypersensitivity Prevalence and Presentation – A Survey-based Study of an Allergic Adult Population in a Toronto Clinic at Onset of Canadian Legalization of Recreational Marijuana
Authors: Shun Chi Ryan Lo, Mina Abbaslou, Khaldon Abbas, Deena Kobric, William Silvers, Gordon Sussman
Journal: Journal of Allergy and Clinical Immunology (2020)
Asthma-Guidance and Prediction System (a-GPS) As a Precision Asthma Care Tool
Authors: Young Juhn, Chung-Il Wi, Sunghwan Sohn, Euijung Ryu, Miguel Park, Joy Fladager Muth, HeeYun Seol, Sungrim Moon, Katherine King, Philip Wheeler, Hongfang Liu, Kathy Ihrke, Deborah McWilliams
Journal: Journal of Allergy and Clinical Immunology (2020)
Experience Transitioning Peanut-Allergic Children to Real Food Equivalents of Peanut after Clinical Trial Participation
Authors: Mary Grace Baker, Amanda Cox, Jake Kattan, Marion Groetch, Allison Schaible, Roxanne Oriel, Angela Tsuang, Anna Nowak-Wegrzyn, Julie Wang, Scott Sicherer
Journal: Journal of Allergy and Clinical Immunology (2020)
Utility of an EMR-Tool to Monitor Total Steroid Burden in Patients with Atopic Dermatitis and Asthma
Authors: Sonam Sani, Erin Banta, Stephanie Mawhirt, Irum Noor, Amanda Schneider, Stacy Nassau, Eleanor Feldman, Luz Fonacier
Journal: Journal of Allergy and Clinical Immunology (2020)
Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China
Authors: Shijun Xia, Xin Du, Lizhu Guo, Jing Du, Clare Arnott, Carolyn S.P. Lam, Mark D. Huffman, Hisatomi Arima, Yiqiang Yuan, Yang Zheng, Shulin Wu, Xuefeng Guang, Xianhui Zhou, Hongbo Lin, Xiaoshu Cheng, Craig S. Anderson, Jianzeng Dong, Changsheng Ma
Journal: Circulation (2020)

Despite improvements in diagnostic and therapeutic interventions to combat cardiovascular disease (CVD) in recent decades, there are significant ongoing access gaps and sex disparities in prevention that have not been adequately quantified in China. A representative, cross-sectional, community-based survey of adults (aged ≥45 years) was conducted in 7 geographic regions of China between 2014 and 2016. Logistic regression models were used to determine sex differences in primary and secondary CVD prevention, and any interaction by age, education level, and area of residence. Data are presented as adjusted odds ratios (ORs) and 95% CIs. Of 47 841 participants (61.3% women), 5454 (57.2% women) had established CVD and 9532 (70.5% women) had a high estimated 10-year CVD risk (≥10%). Only 48.5% and 48.6% of women and 39.3% and 59.8% of men were on any kind of blood pressure (BP)-lowering medication, lipid-lowering medication, or antiplatelet therapy for primary and secondary prevention, respectively. Women with established CVD were significantly less likely than men to receive BP-lowering medications (OR, 0.79 [95% CI, 0.65-0.95]), lipid-lowering medications (OR, 0.69 [95% CI, 0.56-0.84]), antiplatelets (OR, 0.53 [95% CI, 0.45-0.62]), or any CVD prevention medication (OR, 0.62 [95% CI, 0.52-0.73]). Women with established CVD, however, had better BP control (OR, 1.31 [95% CI, 1.14-1.50]) but less well-controlled low-density lipoprotein cholesterol (OR, 0.66 [95% CI, 0.57-0.76]), and were less likely to smoke (OR, 13.89 [95% CI, 11.24-17.15]) and achieve physical activity targets (OR, 1.92 [95% CI, 1.61-2.29]). Conversely, women with high CVD risk were less likely than men to have their BP, low-density lipoprotein cholesterol, and bodyweight controlled (OR, 0.46 [95% CI, 0.38-0.55]; OR, 0.60 [95% CI, 0.52-0.69]; OR, 0.55 [95% CI, 0.48-0.63], respectively), despite a higher use of BP-lowering medications (OR, 1.21 [95% CI, 1.01-1.45]). Younger patients (<65 years) with established CVD were less likely to be taking CVD preventive medications, but there were no sex differences by area of residence or education level. Large and variable gaps in primary and secondary CVD prevention exist in China, particularly for women. Effective CVD prevention requires an improved overall nationwide strategy and a special emphasis on women with established CVD, who have the greatest disparity and the most to benefit.
Prevalence of ARV7 in Asian metastatic castrate-resistant prostate cancer (mCRPC) patients using multiple detection platforms.
Authors: Johan Chan, Whee Sze Ong, Quan Sing Ng, Chee-Keong Toh, Tanujaa Rajasekaran, Wan Ling Tan, Hui Shan Tan, Min-Han Tan, Kiat Hon Lim, Yifang Lee, Siew Wei Wong, Alvin SC Wong, Marniza Bte Saad, Chi-Fai Ng, Phichai Chansriwong, Shigeo Horie, Ravindran Kanesvaran
Journal: Journal of Clinical Oncology (2020)

245 Background: The presence of AR-V7 in metastatic castrate resistant prostate cancer (mCRPC) men has been associated with worse outcome in men initiated on 2nd generation androgen receptor signalling inhibitors (ARSI) in the Caucasian population. A multinational study was conducted to investigate this in the Asian population. Methods: mCRPC patients were recruited prospectively across 5 countries. Blood samples were collected and processed from patients with progressive disease immediately before the initiation of a new treatment and at progression. AR-V7 detection were performed using 3 methods: CTC enrichment followed by automated immunofluorescent staining (Clearbridge [CB]), CTC enrichment followed by reverse-transcription PCR analysis (IBN), and the AdnaTest Prostate Cancer(Adna) platform for CTC analysis and detection. Only blood samples collected in Singapore underwent all 3 methods of detecting AR-V7. Comparison of AR-V7 prevalence using the 3 detection methods were done on patients with the AdnaTest platform as gold standard. We examined associations between AR-V7 status and PSA response rates, PSA progression free survival and overall survival(OS). Results: 102 patients were recruited. 72 patients had ARSi while 30 patients had chemotherapy. 66 patients were included for the comparison of AR-V7 detection methods. AR-V7 prevalence rate was 14.3% (95% CI 4.8-30.3), 21.6% (95% CI 12.9-32.7) and 33.7% (95% CI 24.6-43.8) based on Adna, CB and IBN respectively. Concordance between Adna and CB was 75% while Adna and IBN was 68%. AR-V7- patients had a trend towards higher PSA response, lower risk of PSA progression as compared to AR-V7+ patients. AR-V7- patients had a significantly lower risk of death as compared to AR-V7+ patients detected by Adna and IBN platforms but not the CB platform. The association between ARV7 status and outcomes did not vary when compared across treatment groups. Conclusions: AR-V7 positivity in Asian mCRPC patients is consistent with the data reported in Western populations with lower PSA response rates, PSA progression free survival and OS. This data suggest that ARV7 is more likely a prognostic than a predictive biomarker. Clinical trial information: 2015/2797.
FDA Says It Supports Cannabis Drug Development via Regulatory Pathways
Authors: Rebecca Voelker
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a
Authors: Yu Lei, Joanne A. Hoogerland, Vincent W. Bloks, Trijnie Bos, Aycha Bleeker, Henk Wolters, Justina C. Wolters, Brenda S. Hijmans, Theo H. van Dijk, Rachel Thomas, Michel van Weeghel, Gilles Mithieux, Riekelt H. Houtkooper, Alain de Bruin, Fabienne Rajas, Folkert Kuipers, Maaike H. Oosterveer
Journal: Hepatology (2020)

Glycogen storage disease (GSD) type 1a is an inborn error of metabolism caused by defective glucose-6-phosphatase catalytic subunit (G6PC) activity. Patients with GSD 1a exhibit severe hepatomegaly due to glycogen and triglyceride (TG) accumulation in the liver. We have shown that the activity of carbohydrate response element binding protein (ChREBP), a key regulator of glycolysis and de novo lipogenesis, is increased in GSD 1a. In the current study, we assessed the contribution of ChREBP to nonalcoholic fatty liver disease (NAFLD) development in a mouse model for hepatic GSD 1a.Liver-specific G6pc-knockout (L-G6pc-/- ) mice were treated with adeno-associated viruses (AAVs) 2 or 8 directed against short hairpin ChREBP to normalize hepatic ChREBP activity to levels observed in wild-type mice receiving AAV8-scrambled short hairpin RNA (shSCR). Hepatic ChREBP knockdown markedly increased liver weight and hepatocyte size in L-G6pc-/- mice. This was associated with hepatic accumulation of G6P, glycogen, and lipids, whereas the expression of glycolytic and lipogenic genes was reduced. Enzyme activities, flux measurements, hepatic metabolite analysis and very low density lipoprotein (VLDL)-TG secretion assays revealed that hepatic ChREBP knockdown reduced downstream glycolysis and de novo lipogenesis but also strongly suppressed hepatic VLDL lipidation, hence promoting the storage of "old fat." Interestingly, enhanced VLDL-TG secretion in shSCR-treated L-G6pc-/- mice associated with a ChREBP-dependent induction of the VLDL lipidation proteins microsomal TG transfer protein and transmembrane 6 superfamily member 2 (TM6SF2), the latter being confirmed by ChIP-qPCR.Attenuation of hepatic ChREBP induction in GSD 1a liver aggravates hepatomegaly because of further accumulation of glycogen and lipids as a result of reduced glycolysis and suppressed VLDL-TG secretion. TM6SF2, critical for VLDL formation, was identified as a ChREBP target in mouse liver. Altogether, our data show that enhanced ChREBP activity limits NAFLD development in GSD 1a by balancing hepatic TG production and secretion.
Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma
Authors: Tanaya Shree, Qian Li, Sally L. Glaser, Ann Brunson, Holden T. Maecker, Robert W. Haile, Ronald Levy, Theresa H. M. Keegan
Journal: Journal of Clinical Oncology (2020)

Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an increasing number of survivors. Both DLBCL and its treatments perturb the immune system, yet little is known about immune health during extended survivorship.
Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine
Authors: S. Pützer, L. Varghese, J. von Jan, T. Braun, A. K. Giri, P. Mayer, N. Riet, S. Timonen, S. Oberbeck, H. Kuusanmäki, S. Mustjoki, M.-H. Stern, T. Aittokallio, S. Newrzela, A. Schrader, M. Herling
Journal: Leukemia (2020)